The global market for Dementia Associated with Alzimer’s Disease was valued at US$ 4428 million in the year 2024 and is projected to reach a revised size of US$ 5269 million by 2031, growing at a CAGR of 2.6% during the forecast period.

Dementia Associated with Alzimer’s Disease Market

The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market,

North American market for Dementia Associated with Alzimer’s Disease is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Dementia Associated with Alzimer’s Disease is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Dementia Associated with Alzimer’s Disease in Hospital Pharmacies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Dementia Associated with Alzimer’s Disease include Merz Pharma, Novartis, Allergan, Pfizer, Daiichi Sankyo Company, Ono Pharmaceutical, Johnson & Johnson, Eisai, H. Lundbeck, F. Hoffmann-La Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Dementia Associated with Alzimer’s Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dementia Associated with Alzimer’s Disease.

The Dementia Associated with Alzimer’s Disease market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dementia Associated with Alzimer’s Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Dementia Associated with Alzimer’s Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Dementia Associated with Alzimer’s Disease Market Report

Report Metric	Details
Report Name	Dementia Associated with Alzimer’s Disease Market
Accounted market size in year	US$ 4428 million
Forecasted market size in 2031	US$ 5269 million
CAGR	2.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Cholinergic/ Cholinesterase (ChE) Inhibitors Memantine Combined Drug (Memantine & Donepezil) Others
Segment by Application	Hospital Pharmacies Retail Online Sales
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merz Pharma, Novartis, Allergan, Pfizer, Daiichi Sankyo Company, Ono Pharmaceutical, Johnson & Johnson, Eisai, H. Lundbeck, F. Hoffmann-La Roche
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dementia Associated with Alzimer’s Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Dementia Associated with Alzimer’s Disease Market growing?

Ans: The Dementia Associated with Alzimer’s Disease Market witnessing a CAGR of 2.6% during the forecast period 2025-2031.

What is the Dementia Associated with Alzimer’s Disease Market size in 2031?

Ans: The Dementia Associated with Alzimer’s Disease Market size in 2031 will be US$ 5269 million.

Who are the main players in the Dementia Associated with Alzimer’s Disease Market report?

Ans: The main players in the Dementia Associated with Alzimer’s Disease Market are Merz Pharma, Novartis, Allergan, Pfizer, Daiichi Sankyo Company, Ono Pharmaceutical, Johnson & Johnson, Eisai, H. Lundbeck, F. Hoffmann-La Roche

What are the Application segmentation covered in the Dementia Associated with Alzimer’s Disease Market report?

Ans: The Applications covered in the Dementia Associated with Alzimer’s Disease Market report are Hospital Pharmacies, Retail, Online Sales

What are the Type segmentation covered in the Dementia Associated with Alzimer’s Disease Market report?

Ans: The Types covered in the Dementia Associated with Alzimer’s Disease Market report are Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combined Drug (Memantine & Donepezil), Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Cholinergic/ Cholinesterase (ChE) Inhibitors

1.2.3 Memantine

1.2.4 Combined Drug (Memantine & Donepezil)

1.2.5 Others

1.3 Market by Application

1.3.1 Global Dementia Associated with Alzimer’s Disease Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail

1.3.4 Online Sales

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Dementia Associated with Alzimer’s Disease Market Perspective (2020-2031)

2.2 Global Dementia Associated with Alzimer’s Disease Growth Trends by Region

2.2.1 Global Dementia Associated with Alzimer’s Disease Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Dementia Associated with Alzimer’s Disease Historic Market Size by Region (2020-2025)

2.2.3 Dementia Associated with Alzimer’s Disease Forecasted Market Size by Region (2026-2031)

2.3 Dementia Associated with Alzimer’s Disease Market Dynamics

2.3.1 Dementia Associated with Alzimer’s Disease Industry Trends

2.3.2 Dementia Associated with Alzimer’s Disease Market Drivers

2.3.3 Dementia Associated with Alzimer’s Disease Market Challenges

2.3.4 Dementia Associated with Alzimer’s Disease Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Dementia Associated with Alzimer’s Disease Players by Revenue

3.1.1 Global Top Dementia Associated with Alzimer’s Disease Players by Revenue (2020-2025)

3.1.2 Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Players (2020-2025)

3.2 Global Dementia Associated with Alzimer’s Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Dementia Associated with Alzimer’s Disease Revenue

3.4 Global Dementia Associated with Alzimer’s Disease Market Concentration Ratio

3.4.1 Global Dementia Associated with Alzimer’s Disease Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Dementia Associated with Alzimer’s Disease Revenue in 2024

3.5 Global Key Players of Dementia Associated with Alzimer’s Disease Head office and Area Served

3.6 Global Key Players of Dementia Associated with Alzimer’s Disease, Product and Application

3.7 Global Key Players of Dementia Associated with Alzimer’s Disease, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Dementia Associated with Alzimer’s Disease Breakdown Data by Type

4.1 Global Dementia Associated with Alzimer’s Disease Historic Market Size by Type (2020-2025)

4.2 Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Type (2026-2031)

5 Dementia Associated with Alzimer’s Disease Breakdown Data by Application

5.1 Global Dementia Associated with Alzimer’s Disease Historic Market Size by Application (2020-2025)

5.2 Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Dementia Associated with Alzimer’s Disease Market Size (2020-2031)

6.2 North America Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025)

6.4 North America Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Dementia Associated with Alzimer’s Disease Market Size (2020-2031)

7.2 Europe Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025)

7.4 Europe Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size (2020-2031)

8.2 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size by Region (2020-2025)

8.4 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Dementia Associated with Alzimer’s Disease Market Size (2020-2031)

9.2 Latin America Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025)

9.4 Latin America Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size (2020-2031)

10.2 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025)

10.4 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Merz Pharma

11.1.1 Merz Pharma Company Details

11.1.2 Merz Pharma Business Overview

11.1.3 Merz Pharma Dementia Associated with Alzimer’s Disease Introduction

11.1.4 Merz Pharma Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.1.5 Merz Pharma Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Dementia Associated with Alzimer’s Disease Introduction

11.2.4 Novartis Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.2.5 Novartis Recent Development

11.3 Allergan

11.3.1 Allergan Company Details

11.3.2 Allergan Business Overview

11.3.3 Allergan Dementia Associated with Alzimer’s Disease Introduction

11.3.4 Allergan Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.3.5 Allergan Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Details

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Dementia Associated with Alzimer’s Disease Introduction

11.4.4 Pfizer Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.4.5 Pfizer Recent Development

11.5 Daiichi Sankyo Company

11.5.1 Daiichi Sankyo Company Company Details

11.5.2 Daiichi Sankyo Company Business Overview

11.5.3 Daiichi Sankyo Company Dementia Associated with Alzimer’s Disease Introduction

11.5.4 Daiichi Sankyo Company Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.5.5 Daiichi Sankyo Company Recent Development

11.6 Ono Pharmaceutical

11.6.1 Ono Pharmaceutical Company Details

11.6.2 Ono Pharmaceutical Business Overview

11.6.3 Ono Pharmaceutical Dementia Associated with Alzimer’s Disease Introduction

11.6.4 Ono Pharmaceutical Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.6.5 Ono Pharmaceutical Recent Development

11.7 Johnson & Johnson

11.7.1 Johnson & Johnson Company Details

11.7.2 Johnson & Johnson Business Overview

11.7.3 Johnson & Johnson Dementia Associated with Alzimer’s Disease Introduction

11.7.4 Johnson & Johnson Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.7.5 Johnson & Johnson Recent Development

11.8 Eisai

11.8.1 Eisai Company Details

11.8.2 Eisai Business Overview

11.8.3 Eisai Dementia Associated with Alzimer’s Disease Introduction

11.8.4 Eisai Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.8.5 Eisai Recent Development

11.9 H. Lundbeck

11.9.1 H. Lundbeck Company Details

11.9.2 H. Lundbeck Business Overview

11.9.3 H. Lundbeck Dementia Associated with Alzimer’s Disease Introduction

11.9.4 H. Lundbeck Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.9.5 H. Lundbeck Recent Development

11.10 F. Hoffmann-La Roche

11.10.1 F. Hoffmann-La Roche Company Details

11.10.2 F. Hoffmann-La Roche Business Overview

11.10.3 F. Hoffmann-La Roche Dementia Associated with Alzimer’s Disease Introduction

11.10.4 F. Hoffmann-La Roche Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025)

11.10.5 F. Hoffmann-La Roche Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Daiichi Sankyo Company

List of Tables

Table 1. Global Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Cholinergic/ Cholinesterase (ChE) Inhibitors

Table 3. Key Players of Memantine

Table 4. Key Players of Combined Drug (Memantine & Donepezil)

Table 5. Key Players of Others

Table 6. Global Dementia Associated with Alzimer’s Disease Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Dementia Associated with Alzimer’s Disease Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Dementia Associated with Alzimer’s Disease Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Dementia Associated with Alzimer’s Disease Market Share by Region (2020-2025)

Table 10. Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Dementia Associated with Alzimer’s Disease Market Share by Region (2026-2031)

Table 12. Dementia Associated with Alzimer’s Disease Market Trends

Table 13. Dementia Associated with Alzimer’s Disease Market Drivers

Table 14. Dementia Associated with Alzimer’s Disease Market Challenges

Table 15. Dementia Associated with Alzimer’s Disease Market Restraints

Table 16. Global Dementia Associated with Alzimer’s Disease Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Dementia Associated with Alzimer’s Disease Market Share by Players (2020-2025)

Table 18. Global Top Dementia Associated with Alzimer’s Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dementia Associated with Alzimer’s Disease as of 2024)

Table 19. Ranking of Global Top Dementia Associated with Alzimer’s Disease Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Dementia Associated with Alzimer’s Disease Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Dementia Associated with Alzimer’s Disease, Headquarters and Area Served

Table 22. Global Key Players of Dementia Associated with Alzimer’s Disease, Product and Application

Table 23. Global Key Players of Dementia Associated with Alzimer’s Disease, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Dementia Associated with Alzimer’s Disease Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Type (2020-2025)

Table 27. Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Type (2026-2031)

Table 29. Global Dementia Associated with Alzimer’s Disease Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Application (2020-2025)

Table 31. Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Application (2026-2031)

Table 33. North America Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size by Country (2026-2031) & (US$ Million)

Table 48. Merz Pharma Company Details

Table 49. Merz Pharma Business Overview

Table 50. Merz Pharma Dementia Associated with Alzimer’s Disease Product

Table 51. Merz Pharma Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 52. Merz Pharma Recent Development

Table 53. Novartis Company Details

Table 54. Novartis Business Overview

Table 55. Novartis Dementia Associated with Alzimer’s Disease Product

Table 56. Novartis Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 57. Novartis Recent Development

Table 58. Allergan Company Details

Table 59. Allergan Business Overview

Table 60. Allergan Dementia Associated with Alzimer’s Disease Product

Table 61. Allergan Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 62. Allergan Recent Development

Table 63. Pfizer Company Details

Table 64. Pfizer Business Overview

Table 65. Pfizer Dementia Associated with Alzimer’s Disease Product

Table 66. Pfizer Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 67. Pfizer Recent Development

Table 68. Daiichi Sankyo Company Company Details

Table 69. Daiichi Sankyo Company Business Overview

Table 70. Daiichi Sankyo Company Dementia Associated with Alzimer’s Disease Product

Table 71. Daiichi Sankyo Company Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 72. Daiichi Sankyo Company Recent Development

Table 73. Ono Pharmaceutical Company Details

Table 74. Ono Pharmaceutical Business Overview

Table 75. Ono Pharmaceutical Dementia Associated with Alzimer’s Disease Product

Table 76. Ono Pharmaceutical Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 77. Ono Pharmaceutical Recent Development

Table 78. Johnson & Johnson Company Details

Table 79. Johnson & Johnson Business Overview

Table 80. Johnson & Johnson Dementia Associated with Alzimer’s Disease Product

Table 81. Johnson & Johnson Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 82. Johnson & Johnson Recent Development

Table 83. Eisai Company Details

Table 84. Eisai Business Overview

Table 85. Eisai Dementia Associated with Alzimer’s Disease Product

Table 86. Eisai Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 87. Eisai Recent Development

Table 88. H. Lundbeck Company Details

Table 89. H. Lundbeck Business Overview

Table 90. H. Lundbeck Dementia Associated with Alzimer’s Disease Product

Table 91. H. Lundbeck Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 92. H. Lundbeck Recent Development

Table 93. F. Hoffmann-La Roche Company Details

Table 94. F. Hoffmann-La Roche Business Overview

Table 95. F. Hoffmann-La Roche Dementia Associated with Alzimer’s Disease Product

Table 96. F. Hoffmann-La Roche Revenue in Dementia Associated with Alzimer’s Disease Business (2020-2025) & (US$ Million)

Table 97. F. Hoffmann-La Roche Recent Development

Table 98. Research Programs/Design for This Report

Table 99. Key Data Information from Secondary Sources

Table 100. Key Data Information from Primary Sources

Table 101. Authors List of This Report

List of Figures

Figure 1. Dementia Associated with Alzimer’s Disease Picture

Figure 2. Global Dementia Associated with Alzimer’s Disease Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Dementia Associated with Alzimer’s Disease Market Share by Type: 2024 VS 2031

Figure 4. Cholinergic/ Cholinesterase (ChE) Inhibitors Features

Figure 5. Memantine Features

Figure 6. Combined Drug (Memantine & Donepezil) Features

Figure 7. Others Features

Figure 8. Global Dementia Associated with Alzimer’s Disease Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Dementia Associated with Alzimer’s Disease Market Share by Application: 2024 VS 2031

Figure 10. Hospital Pharmacies Case Studies

Figure 11. Retail Case Studies

Figure 12. Online Sales Case Studies

Figure 13. Dementia Associated with Alzimer’s Disease Report Years Considered

Figure 14. Global Dementia Associated with Alzimer’s Disease Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Dementia Associated with Alzimer’s Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Dementia Associated with Alzimer’s Disease Market Share by Region: 2024 VS 2031

Figure 17. Global Dementia Associated with Alzimer’s Disease Market Share by Players in 2024

Figure 18. Global Top Dementia Associated with Alzimer’s Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dementia Associated with Alzimer’s Disease as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Dementia Associated with Alzimer’s Disease Revenue in 2024

Figure 20. North America Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Dementia Associated with Alzimer’s Disease Market Share by Country (2020-2031)

Figure 22. United States Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Dementia Associated with Alzimer’s Disease Market Share by Country (2020-2031)

Figure 26. Germany Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Dementia Associated with Alzimer’s Disease Market Share by Region (2020-2031)

Figure 34. China Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Dementia Associated with Alzimer’s Disease Market Share by Country (2020-2031)

Figure 42. Mexico Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Dementia Associated with Alzimer’s Disease Market Share by Country (2020-2031)

Figure 46. Turkey Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Dementia Associated with Alzimer’s Disease Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Merz Pharma Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 50. Novartis Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 51. Allergan Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 52. Pfizer Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 53. Daiichi Sankyo Company Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 54. Ono Pharmaceutical Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 55. Johnson & Johnson Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 56. Eisai Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 57. H. Lundbeck Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 58. F. Hoffmann-La Roche Revenue Growth Rate in Dementia Associated with Alzimer’s Disease Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions